300 related articles for article (PubMed ID: 22902995)
21. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer.
Seo JH; Jung KH; Son MK; Yan HH; Ryu YL; Kim J; Lee JK; Hong S; Hong SS
Cancer Lett; 2013 Sep; 338(2):271-81. PubMed ID: 23587795
[TBL] [Abstract][Full Text] [Related]
22. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
24. GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway.
Lu S; Gao Y; Huang X; Wang X
Int J Oncol; 2014 Apr; 44(4):1259-67. PubMed ID: 24535538
[TBL] [Abstract][Full Text] [Related]
25. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
26. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
27. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
Hong SW; Jung KH; Lee HS; Son MK; Yan HH; Kang NS; Lee J; Hong SS
Carcinogenesis; 2013 Sep; 34(9):2156-69. PubMed ID: 23671132
[TBL] [Abstract][Full Text] [Related]
28. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
29. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
31. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
[TBL] [Abstract][Full Text] [Related]
32. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
33. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
34. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
Ryu YL; Jung KH; Son MK; Yan HH; Kim SJ; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Oct; 353(1):68-77. PubMed ID: 25016056
[TBL] [Abstract][Full Text] [Related]
35. An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma.
Jung KH; Rumman M; Yan H; Cheon MJ; Choi JG; Jin X; Park S; Oh MS; Hong SS
Phytother Res; 2018 Oct; 32(10):2034-2046. PubMed ID: 29972254
[TBL] [Abstract][Full Text] [Related]
36. Small molecular anticancer agent SKLB703 induces apoptosis in human hepatocellular carcinoma cells via the mitochondrial apoptotic pathway invitro and inhibits tumor growth invivo.
Xu YZ; Zheng RL; Zhou Y; Peng F; Lin HJ; Bu Q; Mao YQ; Yu LT; Yang L; Yang SY; Zhao YL
Cancer Lett; 2011 Dec; 313(1):44-53. PubMed ID: 21944661
[TBL] [Abstract][Full Text] [Related]
37. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.
Jia WD; Xu GL; Xu RN; Sun HC; Wang L; Yu JH; Wang J; Li JS; Zhai ZM; Xue Q
J Cancer Res Clin Oncol; 2003 Jun; 129(6):327-34. PubMed ID: 12811549
[TBL] [Abstract][Full Text] [Related]
38. A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer.
Lee H; Li GY; Jeong Y; Jung KH; Lee JH; Ham K; Hong S; Hong SS
Cancer Lett; 2012 May; 318(1):68-75. PubMed ID: 22155744
[TBL] [Abstract][Full Text] [Related]
39. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
Kim SJ; Jung KH; Son MK; Park JH; Yan HH; Fang Z; Kang YW; Han B; Lim JH; Hong SS
Cancer Lett; 2017 Sep; 403():339-353. PubMed ID: 28688971
[TBL] [Abstract][Full Text] [Related]
40. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.
Semela D; Piguet AC; Kolev M; Schmitter K; Hlushchuk R; Djonov V; Stoupis C; Dufour JF
J Hepatol; 2007 May; 46(5):840-8. PubMed ID: 17321636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
